CN Patent

CN120051297A — 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法

Assigned to Indapta Therapeutics Inc · Expires 2025-05-27 · 1y expired

What this patent protects

本文提供了治疗方法和用途，其涉及含有缺乏FcRγ链的表达的NK细胞(g‑NK细胞)的组合物与单克隆抗体组合的给药，所述NK细胞用重组嵌合抗原受体(CAR)进行工程化。所提供的方法和用途包括治疗癌症如多发性骨髓瘤或淋巴瘤的方法和用途。

USPTO Abstract

本文提供了治疗方法和用途，其涉及含有缺乏FcRγ链的表达的NK细胞(g‑NK细胞)的组合物与单克隆抗体组合的给药，所述NK细胞用重组嵌合抗原受体(CAR)进行工程化。所提供的方法和用途包括治疗癌症如多发性骨髓瘤或淋巴瘤的方法和用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN120051297A
Jurisdiction
CN
Classification
—
Expires
2025-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Indapta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.